BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K
1626 results:

  • 1. [Research Progress of Targeted Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic lymphoma --Review].
    Chen D; Wang MY; Tian C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Reversal Effect of NVP-BEZ235 on Doxorubicin-Resistance in Burkitt lymphoma RAJI Cell Line].
    Li CT; Zhu XP; Wang SX; Peng QY; Zheng Y; Liu SQ; Lu XD; Wang YS; Weng D; Wang D
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):476-482. PubMed ID: 38660855
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Phase II study of novel orally pi3kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma.
    Wang H; Feng J; Liu Y; Qian Z; Gao D; Ran X; Zhou H; Liu L; Wang B; Fang M; Zhou H; Huang Z; Tao S; Chen Z; Su L; Su H; Yang Y; Xie X; Wu H; Sun P; Hu G; Liang A; Li Z
    Signal Transduct Target Ther; 2024 Apr; 9(1):99. PubMed ID: 38627366
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Bupleuri Radix-Paeoniae Radix Alba medicated plasma exerts effects on HepG2 hepatoma cells by regulating miR-1297/PTEN signaling axis].
    Ding L; Wang RY; Zhang F; Wu MS; Chen B; Sun KW
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1073-1081. PubMed ID: 38621914
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.
    Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
    Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) inhibits proliferation and promotes apoptosis of human HEL cells with JAK2 V617F mutation by blocking the JAK/STAT and pi3k/AKT signaling pathways].
    Fan C; Zhang Y; Yang R; Wu X; Zhou J; Xue J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Mar; 40(3):207-214. PubMed ID: 38512030
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Duvelisib: A comprehensive profile.
    Aljohar HI; Al-Abdullah E; Alzoman NZ; Darwish HW; Darwish IA
    Profiles Drug Subst Excip Relat Methodol; 2024; 49():19-40. PubMed ID: 38423708
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Anticancer Action of Silver Nanoparticles in SKBR3 Breast Cancer Cells through Promotion of Oxidative Stress and Apoptosis.
    Vahabirad M; Daei S; Abbasalipourkabir R; Ziamajidi N
    Biomed Res Int; 2024; 2024():7145339. PubMed ID: 38410788
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.
    Judd S; Revon-Riviere G; Grover SA; Deyell RJ; Vanan MI; Lewis VA; Pecheux L; Zorzi AP; Goudie C; Santiago R; Tran TH; Abbott LS; Brossard J; Moorehead P; Alvi S; Portwine C; Denburg A; Whitlock JA; Cohen-Gogo S; Morgenstern DA
    Cancer Med; 2024 Feb; 13(3):e7033. PubMed ID: 38400668
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [Effect of Chlorambucil Combined with Ibrutinib on Mantle Cell lymphoma Cell Line Jeko-1 and Its Related Mechanism].
    Cai NN; Liu WY; Liu ZQ; Gong JH; Lin YL; Wang ZC; Huang YQ; Guo JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):132-137. PubMed ID: 38387911
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Modulation of Apoptotic and Akt/pi3k/mTOR pathways to target Glioblastoma Cells using synthetic compound PGEA-AN.
    Saad S; Hanif F; Simjee SU; Faizi S; Khan L; Ashfaque A
    J Pak Med Assoc; 2024 Feb; 74(1 (Supple-2)):S39-S46. PubMed ID: 38385470
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the pi3k/AKT/mTOR pathway.
    Wu C; Chen S; Wu Z; Xue J; Zhang W; Wang S; Xindong Zhao ; Wu S
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):98. PubMed ID: 38381215
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome.
    Messana VG; Fascì A; Vitale N; Micillo M; Rovere M; Pesce NA; Martines C; Efremov DG; Vaisitti T; Deaglio S
    Blood Adv; 2024 Apr; 8(8):1920-1933. PubMed ID: 38359376
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-
    Liang X; Yu H; Liang R; Feng Z; Saidahmatov A; Sun C; Ren H; Wei X; Zhao J; Yang C; Liu H
    J Med Chem; 2024 Feb; 67(4):2884-2906. PubMed ID: 38349664
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need.
    Zygmunciak P; Robak T; Puła B
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338868
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of pi3k/AKT/mTOR pathway.
    Diab SE; Tayea NA; Elwakil BH; Elshewemi SS; Gad AAEM; Abdulmalek SA; Ghareeb DA; Olama ZA
    Sci Rep; 2024 Jan; 14(1):2433. PubMed ID: 38286826
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Systematic review of mortality and survival rates for APDS.
    Hanson J; Bonnen PE
    Clin Exp Med; 2024 Jan; 24(1):17. PubMed ID: 38280023
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides.
    Bordeaux ZA; Reddy SV; Choi J; Braun G; McKeel J; Lu W; Yossef SM; Ma EZ; West CE; Kwatra SG; Kwatra MM
    Sci Rep; 2024 Jan; 14(1):1955. PubMed ID: 38263212
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Long non-coding RNA small nucleolar RNA host gene 29 drives chronic myeloid leukemia progression via microRNA-483-3p/Casitas B-lineage lymphoma axis-mediated activation of the phosphoinositide 3-kinase/Akt pathway.
    Feng X; Yang L; Liu X; Liu M; Liu L; Liu J; Luo J
    Med Oncol; 2024 Jan; 41(2):60. PubMed ID: 38252204
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. CCDC86 promotes the aggressive behavior of nasopharyngeal carcinoma by positively regulating EGFR and activating the pi3k/Akt signaling.
    Wang Z; Zhou T; Chen X; Zhu X; Liao B; Liu J; Li S; Tan T; Liu Y
    Neoplasma; 2023 Dec; 70(6):761-776. PubMed ID: 38247332
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 82.